Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases

Pertuzumab, a humanized antibody drug, has improved outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, when administered in combination with trastuzumab and other chemotherapies. Cardiotoxicity due to trastuzumab is widely recognized, while data on pert...

Full description

Bibliographic Details
Main Authors: Mayuko Ito, Yoshiya Horimoto, Ritsuko Sasaki, Sakiko Miyazaki, Gotaro Orihata, Mitsue Saito
Format: Article
Language:English
Published: Karger Publishers 2021-02-01
Series:Case Reports in Oncology
Subjects:
breast cancer
cardiotoxicity
left ventricular dysfunction
trastuzumab
pertuzumab
her2
Online Access:https://www.karger.com/Article/FullText/513002

Similar Items

Similar Items